Joohyuk Sohn Selected Research

abemaciclib

1/2022	Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant.
11/2021	MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR+, HER2--Advanced Breast Cancer.
6/2021	Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups.
6/2021	Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2- advanced breast cancer: MONARCH 2 & 3 trials.
12/2020	Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).
1/2020	Health-Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer After Endocrine Therapy.
1/2020	The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial.
11/2017	MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
9/2017	MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Joohyuk Sohn Research Topics

Disease

68	Breast Neoplasms (Breast Cancer) 07/2022 - 01/2010
26	Neoplasms (Cancer) 01/2022 - 01/2010
12	Neoplasm Metastasis (Metastasis) 06/2021 - 12/2013
11	Disease Progression 01/2022 - 01/2019
11	Neutropenia 01/2021 - 12/2013
5	Nausea 07/2020 - 09/2017
4	Triple Negative Breast Neoplasms 03/2022 - 01/2014
3	Pathologic Complete Response 07/2022 - 01/2010
3	Febrile Neutropenia 08/2020 - 03/2016
3	Diarrhea 04/2019 - 09/2017
3	Circulating Neoplastic Cells 01/2017 - 03/2011
2	Interstitial Lung Diseases (Interstitial Lung Disease) 01/2022 - 01/2020
2	Pneumonia (Pneumonitis) 01/2022 - 10/2020
2	Vomiting 07/2020 - 01/2020
2	Fatigue 01/2020 - 09/2017
2	Carcinoma (Carcinomatosis) 01/2020 - 01/2016
2	Alopecia (Baldness) 04/2019 - 06/2017
1	Ovarian Epithelial Carcinoma 01/2021
1	Atrial Fibrillation 01/2021
1	Exanthema (Rash) 01/2021
1	Hyperglycemia 01/2021
1	Hypersensitivity (Allergy) 01/2021
1	Hypokalemia 01/2021
1	Stomach Neoplasms (Stomach Cancer) 01/2021
1	Osteonecrosis (Kienbock's Disease) 01/2020
1	Melanoma (Melanoma, Malignant) 01/2020
1	Body Weight (Weight, Body) 01/2020
1	Pain (Aches) 01/2020

Drug/Important Bio-Agent (IBA)

30	Hormones (Hormone)IBA 03/2022 - 12/2013
9	Fulvestrant (Faslodex)FDA Link 01/2022 - 09/2017
9	abemaciclibIBA 01/2022 - 09/2017
7	human ERBB2 proteinIBA 01/2022 - 11/2017
6	Tamoxifen FDA LinkGeneric 04/2021 - 01/2018
6	Trastuzumab (Herceptin)FDA Link 01/2021 - 01/2012
6	Cyclophosphamide (Cytoxan)FDA LinkGeneric 10/2020 - 12/2013
6	Biomarkers (Surrogate Marker)IBA 11/2019 - 01/2012
5	Paclitaxel (Taxol)FDA LinkGeneric 01/2021 - 01/2012
5	taxaneIBA 10/2020 - 01/2010
4	ribociclibIBA 03/2022 - 01/2018
4	Pharmaceutical PreparationsIBA 01/2022 - 03/2011
4	ErbB Receptors (EGF Receptor)IBA 10/2021 - 11/2018
4	Letrozole (Femara)FDA LinkGeneric 05/2021 - 01/2018
4	Everolimus FDA Link 05/2021 - 11/2019
4	AnthracyclinesIBA 10/2020 - 01/2010
4	Cyclin-Dependent Kinase 4IBA 08/2020 - 09/2017
4	Estrogen ReceptorsIBA 02/2020 - 01/2017
4	Doxorubicin (Adriamycin)FDA LinkGeneric 04/2019 - 12/2013
3	Aromatase InhibitorsIBA 06/2021 - 11/2017
3	Gonadotropin-Releasing Hormone (GnRH)FDA Link 01/2021 - 10/2018
3	Messenger RNA (mRNA)IBA 12/2020 - 01/2017
3	palbociclibIBA 08/2020 - 12/2019
3	eribulin FDA Link 11/2019 - 04/2017
3	ParaffinIBA 01/2018 - 01/2012
3	Epidermal Growth Factor (EGF)IBA 01/2016 - 01/2012
2	Carboplatin (JM8)FDA LinkGeneric 07/2022 - 01/2021
2	trastuzumab deruxtecanIBA 01/2022 - 01/2020
2	Leuprolide (Lupron)FDA LinkGeneric 05/2021 - 01/2021
2	PlatinumIBA 01/2021 - 01/2020
2	Goserelin (Zoladex)FDA Link 01/2021 - 11/2018
2	Alanine Transaminase (SGPT)IBA 01/2021 - 01/2021
2	HM781-36BIBA 12/2020 - 01/2019
2	Immunoglobulin G (IgG)IBA 01/2020 - 01/2012
2	Monoclonal AntibodiesIBA 01/2020 - 01/2020
2	Lapatinib (GW572016)FDA Link 12/2019 - 10/2019
2	Gemcitabine FDA Link 11/2019 - 01/2019
2	Cyclin DIBA 01/2019 - 01/2019
2	Docetaxel (Taxotere)FDA Link 03/2016 - 12/2013
2	Formaldehyde (Formol)FDA Link 01/2015 - 01/2012
1	Phenobarbital (Luminal)FDA Link 03/2022
1	talazoparibIBA 10/2021
1	Progesterone Receptors (Progesterone Receptor)IBA 06/2021
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2021
1	Circulating Tumor DNAIBA 01/2021
1	DNA (Deoxyribonucleic Acid)IBA 01/2021
1	AlpelisibIBA 01/2021
1	NVP-BKM120IBA 01/2021
1	CT-P6IBA 01/2021
1	avelumabIBA 01/2021
1	Biosimilar PharmaceuticalsIBA 01/2021
1	130-nm albumin-bound paclitaxelIBA 10/2020
1	atezolizumabIBA 10/2020
1	LigandsIBA 10/2020
1	TOR Serine-Threonine KinasesIBA 08/2020
1	ramosetron (Nasea)IBA 07/2020
1	Palonosetron (Aloxi)FDA Link 07/2020
1	Dexamethasone (Maxidex)FDA LinkGeneric 07/2020
1	Aprepitant (Emend)FDA Link 07/2020
1	CalciumIBA 04/2020
1	sacituzumab govitecanIBA 04/2020
1	Immunoconjugates (Immunoconjugate)IBA 02/2020
1	Immunoglobulins (Immunoglobulin)IBA 01/2020
1	CTLA-4 AntigenIBA 01/2020
1	tremelimumabIBA 01/2020

Therapy/Procedure

31	Therapeutics 03/2022 - 12/2013
22	Drug Therapy (Chemotherapy) 01/2022 - 12/2013
8	Neoadjuvant Therapy 01/2021 - 01/2010
4	Adjuvant Chemotherapy 01/2020 - 03/2016
2	Radiotherapy 01/2018 - 09/2017
1	Drug Tapering 01/2021
1	Intravenous Infusions 01/2020